NASDAQ:AKBA - Akebia Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.83
  • Forecasted Upside: 217.14 %
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$2.47
▼ -0.08 (-3.14%)

This chart shows the closing price for AKBA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Akebia Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKBA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKBA

Analyst Price Target is $7.83
▲ +217.14% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is $7.83, with a high forecast of $18.00 and a low forecast of $3.00. The average price target represents a 217.14% upside from the last price of $2.47.

This chart shows the closing price for AKBA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Akebia Therapeutics. This rating has held steady since February 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
7/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/8/2021Cantor FitzgeraldInitiated CoverageOverweight$8.00High
3/8/2021HC WainwrightLower Price TargetBuy$9.00 ➝ $6.00Low
1/29/2021JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightMedium
10/26/2020HC WainwrightLower Price TargetBuy$10.00 ➝ $9.00High
9/4/2020Morgan StanleyLower Price TargetEqual Weight$12.00 ➝ $3.00High
9/4/2020BTIG ResearchLower Price TargetBuy$26.00 ➝ $6.00Medium
9/4/2020HC WainwrightLower Price TargetBuy$17.00 ➝ $10.00Medium
9/4/2020MizuhoLower Price TargetBuy$17.00 ➝ $6.00Medium
9/3/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralMedium
8/11/2020Needham & Company LLCInitiated CoverageBuy$18.00High
8/11/2020MizuhoReiterated RatingBuy$17.00High
7/15/2020Morgan StanleyBoost Price TargetEqual Weight$11.00 ➝ $12.00Medium
7/15/2020HC WainwrightReiterated RatingBuyHigh
6/29/2020Needham & Company LLCInitiated CoverageBuy$18.00High
5/6/2020Royal Bank of CanadaBoost Price TargetPositive ➝ Sector Perform$8.00 ➝ $12.00Low
5/6/2020Morgan StanleyBoost Price TargetEqual Weight$9.00 ➝ $11.00Low
5/6/2020JPMorgan Chase & Co.Boost Price TargetOverweight$13.00 ➝ $18.00Low
5/6/2020MizuhoBoost Price TargetBuy$15.00 ➝ $17.00Medium
5/6/2020HC WainwrightBoost Price TargetBuy$16.00 ➝ $17.00Medium
5/5/2020Needham & Company LLCBoost Price TargetBuy$15.00 ➝ $18.00High
3/19/2020MizuhoReiterated RatingBuy$15.00High
3/11/2020MizuhoLower Price TargetBuy$16.00 ➝ $15.00High
3/10/2020Needham & Company LLCReiterated RatingBuy$15.00High
2/20/2020JPMorgan Chase & Co.Boost Price TargetOverweight$10.00 ➝ $13.00High
2/19/2020HC WainwrightReiterated RatingBuy$16.00High
11/19/2019MizuhoReiterated RatingBuy$16.00Medium
11/14/2019Needham & Company LLCLower Price TargetBuy$18.00 ➝ $15.00Medium
9/9/2019HC WainwrightReiterated RatingBuy$17.00High
8/9/2019MizuhoSet Price TargetBuy$16.00N/A
8/6/2019HC WainwrightLower Price TargetBuy ➝ Buy$19.00 ➝ $17.00High
7/11/2019HC WainwrightReiterated RatingBuy ➝ Buy$23.00 ➝ $21.00Medium
5/2/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$12.00High
3/20/2019CitigroupInitiated CoverageNeutral ➝ Neutral$9.00High
12/4/2018MizuhoReiterated RatingBuy$17.00Medium
9/7/2018Morgan StanleyInitiated CoverageEqual ➝ Equal WeightHigh
9/7/2018Morgan StanleySet Price TargetEqual Weight ➝ Hold$9.00Low
8/13/2018Raymond JamesInitiated CoverageBuy$18.00Medium
8/10/2018Needham & Company LLCLower Price TargetBuy$20.00 ➝ $18.00Medium
8/9/2018Royal Bank of CanadaReiterated RatingHold$13.00Medium
6/29/2018HC WainwrightReiterated RatingBuyHigh
6/6/2018HC WainwrightLower Price TargetBuy$24.00 ➝ $22.00High
5/10/2018MizuhoReiterated RatingBuy$24.00Low
3/13/2018MizuhoReiterated RatingBuy$24.00High
3/7/2018MizuhoSet Price TargetBuy$24.00High
2/13/2018MizuhoReiterated RatingBuy$24.00Low
12/18/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$26.00Medium
12/7/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$30.00Medium
11/15/2017HC WainwrightReiterated RatingBuy$24.00N/A
11/9/2017MizuhoReiterated RatingBuy$24.00N/A
11/2/2017Royal Bank of CanadaReiterated RatingHold$17.00N/A
10/4/2017MizuhoInitiated CoverageBuy$24.00N/A
9/16/2017Royal Bank of CanadaReiterated RatingOutperform$28.00Low
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$17.00High
8/9/2017HC WainwrightReiterated RatingBuy$24.00High
7/10/2017HC WainwrightLower Price TargetBuy ➝ Buy$25.00 ➝ $24.00Medium
6/30/2017AegisReiterated RatingBuyHigh
6/6/2017HC WainwrightReiterated RatingBuy$25.00Medium
6/5/2017AegisReiterated RatingBuyMedium
5/18/2017AegisReiterated RatingBuy$25.00Low
5/17/2017Needham & Company LLCReiterated RatingBuy$18.00 ➝ $21.00Low
5/17/2017HC WainwrightReiterated RatingNeutral$21.00 ➝ $25.00Low
5/5/2017UBS GroupReiterated RatingBuy$12.00 ➝ $17.00N/A
4/28/2017AegisBoost Price TargetBuy$21.00 ➝ $25.00Low
4/27/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$14.00 ➝ $18.00High
4/27/2017HC WainwrightBoost Price TargetBuy ➝ Buy$18.00 ➝ $21.00High
4/26/2017JMP SecuritiesBoost Price TargetOutperform$19.00 ➝ $21.00High
3/24/2017AegisReiterated RatingBuyLow
2/14/2017AegisReiterated RatingBuy$21.00N/A
12/27/2016HC WainwrightBoost Price TargetBuy$17.00 ➝ $18.00N/A
12/20/2016Needham & Company LLCSet Price TargetBuy$14.00N/A
12/20/2016JMP SecuritiesBoost Price TargetOutperform$16.00 ➝ $19.00N/A
11/15/2016AegisInitiated CoverageBuy$18.00N/A
11/10/2016JMP SecuritiesReiterated RatingBuyN/A
9/29/2016Brean CapitalInitiated CoverageBuy$18.00N/A
8/23/2016HC WainwrightReiterated RatingBuyN/A
8/11/2016JMP SecuritiesReiterated RatingMarket Perform$16.00N/A
8/9/2016Credit Suisse GroupReiterated RatingHold$8.00N/A
8/9/2016UBS GroupSet Price TargetBuy$12.00N/A
(Data available from 7/25/2016 forward)
Akebia Therapeutics logo
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $2.47
Low: $2.47
High: $2.61

50 Day Range

MA: $3.48
Low: $2.47
High: $4.20

52 Week Range

Now: $2.47
Low: $2.09
High: $12.48

Volume

6,169,756 shs

Average Volume

4,464,072 shs

Market Capitalization

$395.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Akebia Therapeutics?

The following Wall Street analysts have issued research reports on Akebia Therapeutics in the last twelve months: BTIG Research, Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, and Zacks Investment Research.
View the latest analyst ratings for AKBA.

What is the current price target for Akebia Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Akebia Therapeutics in the last year. Their average twelve-month price target is $7.83, suggesting a possible upside of 217.1%. Needham & Company LLC has the highest price target set, predicting AKBA will reach $18.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $3.00 for Akebia Therapeutics in the next year.
View the latest price targets for AKBA.

What is the current consensus analyst rating for Akebia Therapeutics?

Akebia Therapeutics currently has 1 sell rating, 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AKBA will outperform the market and that investors should add to their positions of Akebia Therapeutics.
View the latest ratings for AKBA.

What other companies compete with Akebia Therapeutics?

How do I contact Akebia Therapeutics' investor relations team?

Akebia Therapeutics' physical mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company's listed phone number is 617-871-2098 and its investor relations email address is [email protected] The official website for Akebia Therapeutics is www.akebia.com.